Tag: Multiple Sclerosis

[Articles] Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm trial

Modafinil, CBT, and combination therapy were associated with similar reductions in the effects of multiple sclerosis fatigue at 12 weeks. Combination therapy was not associated with augmented improvement compared with the individual interventions. Further research is needed to determine whether effects of these interventions on multiple sclerosis-related fatigue is influenced by sleep hygiene and sleepiness.… Continue reading [Articles] Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm trial

[Comment] Changing multiple-sclerosis-induced thoughts and behaviours

The COMBO-MS trial, reported in The Lancet Neurology by Tiffany Braley and colleagues,1 is the first pragmatic, randomised, controlled trial that compares head-to-head the benefits and harms of a non-pharmacological treatment, a pharmacological treatment, and a combination of the two for multiple-sclerosis-related fatigue. In this comparative effectiveness trial, 12 weeks of cognitive behavioural therapy (CBT),… Continue reading [Comment] Changing multiple-sclerosis-induced thoughts and behaviours

Do people with MS have an increased risk of cancer?

AI SummaryThe study discusses the potential link between multiple sclerosis (MS) and an increased risk of certain cancers such as bladder, brain, and cervical cancers. While the study does not definitively prove that MS directly causes cancer, it highlights an association between MS and higher incidences of these specific cancer types.A new study has found… Continue reading Do people with MS have an increased risk of cancer?

sNFl and sGFAP Predict MS Disability in Unique Ways

AI SummaryThe content discusses how serum glial fibrillary acidic protein (sGFAP) is becoming a valuable biomarker for predicting disability in patients with multiple sclerosis (MS). This biomarker, along with serum neurofilament light chain (sNFl), can provide unique insights into the progression of MS and its impact on patient outcomes.Serum glial fibrillary acidic protein (sGFAP) is… Continue reading sNFl and sGFAP Predict MS Disability in Unique Ways

New study could lead to a more potent treatment option for multiple sclerosis

AI SummaryThe article discusses the potential for a new treatment option for multiple sclerosis (MS) using tolerogenic dendritic cells (tolDCs) from the same patients. Current treatments weaken the immune system, leaving patients vulnerable to infections and cancer. Researchers are studying CD14+ monocytes, mature dendritic cells (mDCs), and Vitamin D3-treated tolDCs from MS patients and healthy… Continue reading New study could lead to a more potent treatment option for multiple sclerosis

New study finds a promising combined therapy for multiple sclerosis

AI SummaryThe study discusses a new combined therapy approach for treating multiple sclerosis (MS) using Vitamin D3 tolerogenic dendritic cells (VitD3-tolDCs) to regulate the immune response in MS patients. The successful Phase I trials have led to plans for Phase II trials to further investigate this promising treatment method.Researchers have found a potential new way… Continue reading New study finds a promising combined therapy for multiple sclerosis